Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions
- PMID: 35895254
- DOI: 10.1007/s40273-022-01176-0
Tools for the Economic Evaluation of Precision Medicine: A Scoping Review of Frameworks for Valuing Heterogeneity-Informed Decisions
Abstract
Background and objective: Precision medicine highlights the importance of exploring heterogeneity in the effectiveness and costs of interventions. Our objective was to identify and compare frameworks for valuing heterogeneity-informed decisions, and consider their strengths and weaknesses for application to precision medicine.
Methods: We conducted a scoping review to identify papers that proposed an analytical framework to place a value, in terms of costs and health benefits, on using heterogeneity to inform treatment selection. The search included English-language papers indexed in MEDLINE, Embase or EconLit, and a manual review of references and citations. We compared the frameworks qualitatively considering: the purpose and setting of the analysis; the types of precision medicine interventions where the framework could be applied; and the framework's ability to address the methodological challenges of evaluating precision medicine.
Results: Four analytical frameworks were identified: value of stratification, value of heterogeneity, expected value of individualised care and loss with respect to efficient diffusion. Each framework is suited to slightly different settings and research questions. All focus on maximising net benefit, and quantify the opportunity cost of ignoring heterogeneity by comparing individualised or stratified decisions to a means-based population-wide decision. Where the frameworks differ is in their approaches to uncertainty, and in the additional metrics they consider.
Conclusions: Identifying and utilising heterogeneity is at the core of precision medicine, and the ability to quantify the value of heterogeneity-informed decisions is critical. Using an analytical framework to value heterogeneity will help provide evidence to inform investment in precision medicine interventions, appropriately capturing the value of targeted health interventions.
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760. Health Technol Assess. 2021. PMID: 34990339
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001. JBI Libr Syst Rev. 2009. PMID: 27820426
-
Risk management frameworks for human health and environmental risks.J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608. J Toxicol Environ Health B Crit Rev. 2003. PMID: 14698953 Review.
-
Impact of summer programmes on the outcomes of disadvantaged or 'at risk' young people: A systematic review.Campbell Syst Rev. 2024 Jun 13;20(2):e1406. doi: 10.1002/cl2.1406. eCollection 2024 Jun. Campbell Syst Rev. 2024. PMID: 38873396 Free PMC article. Review.
Cited by
-
A Review of Heterogeneity in Comparative Economic Analysis, with Specific Considerations for the Decentralized US Setting and Patient-Centered Care.Pharmacoeconomics. 2025 Jun;43(6):601-616. doi: 10.1007/s40273-025-01478-z. Epub 2025 Mar 8. Pharmacoeconomics. 2025. PMID: 40057662 Free PMC article. Review.
-
Using Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework.Appl Health Econ Health Policy. 2025 May;23(3):441-452. doi: 10.1007/s40258-024-00926-9. Epub 2024 Nov 9. Appl Health Econ Health Policy. 2025. PMID: 39520611
-
Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature.Pharmacoeconomics. 2024 Jul;42(7):737-749. doi: 10.1007/s40273-024-01377-9. Epub 2024 Apr 27. Pharmacoeconomics. 2024. PMID: 38676871 Review.
References
-
- National Research Council. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press; 2011.
-
- Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Health. 2013;16(6 Suppl.):S4-9. https://doi.org/10.1016/j.jval.2013.06.005 . - DOI - PubMed
-
- Burns LC, Orsini L, L’Italien G. Value-based assessment of pharmacodiagnostic testing from early stage development to real-world use. Value Health. 2013;16(6 Suppl.):S16–9. https://doi.org/10.1016/j.jval.2013.06.007 . - DOI - PubMed
-
- Weymann D, et al. The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers. Mol Genet Genomic Med. 2017;5(3):251–60. https://doi.org/10.1002/mgg3.281 . - DOI - PubMed - PMC
-
- Frank M, et al. Genome sequencing: a systematic review of health economic evidence. Health Econ Rev. 2013;3:29. https://doi.org/10.1186/2191-1991-3-29 . - DOI - PubMed - PMC
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources